Recent updates on Sintilimab in solid tumor immunotherapy

A review of cancer immunotherapy toxicity

(2020) Lucy Boyce Kennedy et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC

(2020) Shugeng Gao et al.   Journal of Thoracic Oncology

Complete response to the combination of sintilimab and IBI305 for a patient with HBV-associated hepatocellular carcinoma with multiple lung metastasis

(2020) Xiaohui Duan et al.   DIGESTIVE AND LIVER DISEASE

Marked elevation of creatine phosphokinase alone caused by sintilimab - beware of hypothyroid myopathy

(2020) Jun Ni et al.   EUROPEAN JOURNAL OF CANCER

A metastatic intrahepatic cholangiocarcinoma treated with programmed cell death 1 inhibitor: a case report and literature review

(2020) Jingjing Zhang et al.   Immunotherapy

Promising response to a PD-1 inhibitor (sintilimab) in non-small cell lung cancer

(2020) Lin Zhang et al.   MEDICINE

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-PD-1 Therapy Achieved Disease Control After Multiline Chemotherapy in Unresectable KRAS-Positive Hepatoid Lung Adenocarcinoma: A Case Report and Literature Review

(2020) Lulu Chen et al.   OncoTargets and Therapy

Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma

(2020) Qian Xing et al.   Annals of Translational Medicine

Treatment of advanced intrahepatic cholangiocarcinoma with sintilimab combined with tegafur-gimeracil-oteracil potassium capsules (S-1): a case report

(2020) Jin Liu et al.   Annals of Palliative Medicine

Pulmonary fibrosis and cytokine release syndrome after hyperactivation with sintilimab

(2020) Jing Hu et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Paraneoplastic Encephalitis and Enteric Neuropathy Associated With Anti-Hu Antibody in a Patient Following Immune-checkpoint Inhibitor Therapy

(2020) Kai Kang et al.   JOURNAL OF IMMUNOTHERAPY

Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous non-small cell lung cancer: a randomized, double-blind, phase 3 study (ORIENT-11)

(2020) Yunpeng Yang et al.   Journal of Thoracic Oncology

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

(2020) Michael S Lee et al.   LANCET ONCOLOGY

Unexpected favorable outcome to sintilimab plus bevacizumab in an EGFR ‐mutated non‐small cell lung cancer patient: A case report

(2020) Yiruo Zhang et al.   Thoracic Cancer

Sintilimab as salvage treatment in an HIV patient with relapsed/ refractory Hodgkin: a case report

(2020) Yang Shi et al.   Annals of Palliative Medicine

An esophageal cancer case of cytokine release syndrome with multiple-organ injury induced by an anti-PD-1 drug: a case report

(2020) Chao Gao et al.   Annals of Palliative Medicine

Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial

(2020) Haiping Jiang et al.   BMC CANCER

An update on the immune landscape in lung and head and neck cancers

(2020) Jennifer W. Carlisle et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study

(2020) Haiping Jiang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Duration of immunotherapy in patients with advanced lung adenocarcinoma with negative driver genes: case report and literature review

(2020) Qinge Shan et al.   Thoracic Cancer

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer

(2020) Kohei Shitara et al.   JAMA Oncology

Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma

(2019) Stephen M Ansell   Lancet Haematology

Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial

(2019) Yuankai Shi et al.   Lancet Haematology

Pros and cons of the immunogenicity of monoclonal antibodies in cancer treatment: a lesson from autoimmune diseases

(2019) Rossella Talotta et al.   Immunotherapy

Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study

(2019) Yung-Jue Bang et al.   Gastric Cancer

Sintilimab: First Global Approval

(2019) Sheridan M. Hoy   DRUGS

New era of drug innovation in China

(2019) Xuan Ye et al.   Acta Pharmaceutica Sinica B

Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit

(2019) Jie Wang et al.   mAbs

JCSE01.11 Efficacy and Safety of Sintilimab with Anlotinib as First-Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC)

(2019) B. Han et al.   Journal of Thoracic Oncology

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

(2019) Richard S. Finn et al.   JOURNAL OF CLINICAL ONCOLOGY

New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity

(2018) John A. Thompson   Journal of the National Comprehensive Cancer Network

Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

(2018) Dai Fukumura et al.   Nature Reviews Clinical Oncology

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

(2018) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials

(2018) C. Bryce Johnson et al.   OncoImmunology

Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)

(2018) N Boku et al.   ANNALS OF ONCOLOGY

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

(2015) J. Naidoo et al.   ANNALS OF ONCOLOGY

Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia

(2014) Rakesh K. Jain   CANCER CELL

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY